奈拉滨治疗复发或难治性T系急性淋巴细胞白血病或T系淋巴母细胞淋巴瘤儿童及年轻成人的安全性与疗效:一项4期研究结果
这项4期、多中心、单臂、观察性、开放标签试验在≤21岁儿童及年轻成人中评估奈拉滨获批使用条件下的安全性与疗效,共28例患者。总体缓解率39.3%,完全缓解35.7%,完全缓解伴血液学未完全恢复3.6%。不良事件发生率46%,治疗相关不良事件21%,无因不良事件停药或退出。
要点
- 28例≤21岁患者中,总体缓解率39.3%,完全缓解35.7%,完全缓解伴血液学未完全恢复3.6%。
- 不良事件发生率46%,治疗相关不良事件21%,无血液学严重不良事件。
- 4例报告四类预定类别之一的神经不良事件,无因不良事件停药或退出。
核心结论
- 奈拉滨在该疾病背景和人群中的缓解率、中位总生存期及安全性特征与既往报告一致。
研究设计与样本
- 4期、多中心、单臂、观察性、开放标签试验,纳入28例≤21岁复发或难治性T系急性淋巴细胞白血病或T系淋巴母细胞淋巴瘤患者。
- 患者平均年龄±标准差为11.5±4.6岁,71%为男性,61%诊断为T系急性淋巴细胞白血病。
主要发现
- 不良事件发生率为46%,治疗相关不良事件发生率为21%,包括少量血液学不良事件,无血液学严重不良事件。
- 四类预定类别(周围和中枢神经系统、精神状态改变及未分类)之一的神经不良事件报告于4例患者。
- 无因不良事件导致的治疗中止或退出。
- 总体缓解率为39.3%:完全缓解35.7%,完全缓解伴血液学未完全恢复3.6%。
- 46%的队列在治疗后接受造血干细胞移植;无缓解者中位总生存期为3.35个月,缓解者(完全缓解+完全缓解伴血液学未完全恢复)中位总生存期未达到。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nelarabine is an antineoplastic agent approved for the treatment of relapsed/refractory T-lineage acute lymphoblastic leukaemia (T-ALL) or T-lineage acute lymphoblastic lymphoma (T-LBL). The purpose of this phase 4, multicentre, single-arm, observational, open-label trial was to provide additional data on the safety and efficacy of nelarabine under licensed conditions of use in children and young adults ≤21 years of age. Patients (N = 28) had a mean ± standard deviation age of 11·5 ± 4·6 years; 71% were male and 61% had a diagnosis of T-ALL. Adverse events (AEs) and treatment-related AEs were experienced by 46% and 21%, respectively, and included few haematological AEs and no haematological serious AEs. Neurological AEs from one of four predefined categories (peripheral and central nervous systems, mental status change and uncategorized) were reported in four patients. There were no AE-related treatment discontinuations/withdrawals. The overall response rate was 39.3%: complete response (CR), 35.7%; CR without full haematological recovery (CR*), 3.6%. Post-treatment stem cell transplantation was performed for 46% of the cohort. Median overall survival (OS) was 3·35 months for non-responders and not reached for responders (CR + CR*). The response rate, median OS, and safety profile of nelarabine in this disease setting and population were consistent with those reported previously.
引用
- Zwaan CM, Kowalczyk J, Schmitt C, et al. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. Br J Haematol. 2017. PMID: 28771663. doi:10.1111/bjh.14874
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。